Clinical Trials on Recurrent Platinum-Resistant Ovarian Carcinoma in New Zealand

Total 934 results

Children's Oncology Group
National Cancer Institute (NCI)

Completed

Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant

Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Malignant Neoplasm | Bacterial Infection | Myeloid Neoplasm | Benign Neoplasm | Methicillin-Resistant Staphylococcus Aureus Infection

United States, Canada, Puerto Rico
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer

Ovarian Cancer | Peritoneal Cavity Cancer

United States
SCRI Development Innovations, LLC
Bayer

Completed

Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer

Ovarian Cancer

United States
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Melanoma | Neuroblastoma | Pancreatic Ductal Adenocarcinoma | Refractory Malignant Solid Neoplasm | Endometrial Carcinoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Malignant Solid Neoplasm | Recurrent Non-Hodgkin Lymphoma | Recurrent Osteosarcoma | Refractory Ewing Sarcoma | Refractory... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

Peritoneal Carcinomatosis | Stage IV Uterine Corpus Cancer AJCC v8 | Stage IVA Uterine Corpus Cancer AJCC v8 | Stage IVB Uterine Corpus Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Malignant Uterine Neoplasm | Clinical Stage IV Gastric Cancer AJCC v8 | Metastatic Colorectal Carcinoma | Stage... and other conditions

United States
Astex Pharmaceuticals, Inc.

Completed

SGI-110 in Combination With Carboplatin in Ovarian Cancer (SGI-110)

Ovarian Cancer

Canada, United States, United Kingdom
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Aminocamptothecin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Cancer of the Peritoneum

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
Seagen Inc.
Genmab

Completed

A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States, Spain, Belgium, Denmark, Ireland, Italy
Eli Lilly and Company
Loxo Oncology, Inc.

Recruiting

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

Cervical Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Bladder Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Renal Pelvis Cancer | Urinary Bladder Neoplasm | Recurrent...

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Fallopian Tube Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma

United States
Bayer

Completed

ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer

Ovarian Neoplasms

United States, Canada
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

Photodynamic Therapy Using Methyl-5-Aminolevulinate Hydrochloride Cream in Determining Pain Threshold in Patients With Skin Cancer

Pain | Recurrent Skin Cancer | Basal Cell Carcinoma of the Skin

United States
Hoffmann-La Roche

Terminated

A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer

Triple Negative Breast Cancer | Advanced Ovarian Cancer

United Kingdom, United States, Australia, Denmark, Canada
Gradalis, Inc.

Active, not recruiting

A Trial of Vigil for Participants With Ovarian Cancer (VITAL)

Ovarian Neoplasms | Ovarian Cancer

United States
Imunon

Active, not recruiting

Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) (OVATION 2)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States, Canada
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

Recurrent Thyroid Gland Carcinoma | Poorly Differentiated Thyroid Gland Carcinoma | Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 | Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IVA Thyroid Gland Papillary Carcinoma AJCC... and other conditions

United States
Menarini Group

Terminated

Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients (MIMOSA)

Ovarian Cancer

United States, Spain, Germany, Belgium, France, Czech Republic, Hungary, Italy, Poland
AstraZeneca
Parexel

Withdrawn

A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment. (DUETTE)

Ovarian Cancer

United States, Italy, Canada, Spain
Santa Maria Biotherapeutics

Completed

Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors

Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer | Solid Tumors

United States
Pfizer

Terminated

Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)

Ovarian Cancer

United States, Canada, United Kingdom, Korea, Republic of, Netherlands, Hong Kong, Singapore, Ireland, Estonia, Japan, Taiwan, Italy, Turkey, Slovakia, Germany, Poland, Switzerland, Croatia, Hungary, Bulgaria, Latvia, Mexico, Romania, Russian Federation and more
MEI Pharma, Inc.

Completed

OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer (OVATURE)

Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer

United States, Spain, Belgium, United Kingdom, Australia, Italy, Poland
NCIC Clinical Trials Group
European Organisation for Research and Treatment of Cancer - EORTC; Grupo Español...

Completed

Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic Mass

Ovarian Cancer | Fallopian Tube Cancer

United States
Klus Pharma Inc.

Completed

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Cervical Cancer | Head and Neck Cancer | Mucoepidermoid Carcinoma | Pancreatic Cancer | Recurrent Prostate Cancer | Lung Cancer | Rectal Cancer | Solid Tumor | Prostate Cancer | Cholangiocarcinoma | Bile Duct Cancer | Recurrent Ovarian Carcinoma | Bladder Cancer | Skin Cancer | HER2-positive Breast Cancer | Rare Diseases | Colo-rectal Cancer and other conditions

United States
Morphotek
Eisai Europe Ltd. (United Kingdom)

Terminated

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Ovarian Cancer

United States, Hong Kong, Netherlands, Spain, Korea, Republic of, Belgium, Taiwan, Israel, Japan, France, United Kingdom, Singapore, Italy, Argentina, India, Germany, Hungary, Australia, Portugal, Russian Federation, Canada, Poland, Greec... and more
Roswell Park Cancer Institute

Recruiting

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
Celgene
Gynecologic Oncology Group

Completed

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States
Canadian Cancer Trials Group
Apotex Inc.

Active, not recruiting

ASA in Prevention of Ovarian Cancer (STICs and STONEs)

Ovarian Cancer Prevention

Canada, Australia
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
AGO Study Group

Active, not recruiting

Trial on Radical Upfront Surgery in Advanced Ovarian Cancer (TRUST)

Ovarian Cancer

United States, France, Germany, Austria, Sweden, Denmark, Italy, United Kingdom
Adaptimmune
GOG Foundation

Recruiting

ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)

Ovarian Cancer

United States, Spain, France, Canada, United Kingdom
Roswell Park Cancer Institute
Merck Sharp & Dohme LLC

Terminated

Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer

Recurrent Prostate Cancer | Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Gilead Sciences

Completed

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Cervical Cancer | Urinary Bladder Neoplasms | Small Cell Lung Cancer | Hepatocellular Carcinoma | Pancreatic Cancer | Esophageal Cancer | Ovarian Epithelial Cancer | Glioblastoma Multiforme | Gastric Adenocarcinoma | Triple Negative Breast Cancer | Endometrial Cancer | Non-small Cell Lung Cancer | Renal Cell Cancer and other conditions

United States
Hoffmann-La Roche

Active, not recruiting

An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms

India
Syndax Pharmaceuticals
Pfizer; Merck KGaA, Darmstadt, Germany

Completed

Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

United States
ImmunoGen, Inc.

Active, not recruiting

IMGN853 With Carboplatin in Second-line Treatment of FRα Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Fallopian Tube Cancer | Primary Peritoneal Cancer | High Grade Ovarian Cancer

United States, United Kingdom, Belgium, Spain, Canada, Georgia
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous Adenocarcinoma and other conditions

United States, Korea, Republic of, Canada
Facet Biotech
Biogen

Terminated

A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer

Peritoneal Neoplasms | Ovarian Cancer

United States, Canada
zr Pharma & GmbH
Foundation Medicine; Myriad Genetics, Inc.

Completed

Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) (ARIEL3)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States, Spain, Belgium, Australia, Israel, Germany, France, United Kingdom, Italy, Canada, New Zealand
National Cancer Institute (NCI)

Terminated

Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer

Mucinous Adenocarcinoma of the Rectum | Signet Ring Adenocarcinoma of the Rectum | Mucinous Adenocarcinoma of the Colon | Signet Ring Adenocarcinoma of the Colon | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal...

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
New Mexico Cancer Care Alliance

Active, not recruiting

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer

United States
23andMe, Inc.

Active, not recruiting

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Clear Cell Renal Cell Carcinoma | Fallopian Tube Cancer | Solid Tumor | Neuroendocrine Tumors | Epithelial Ovarian Cancer | Primary Peritoneal Carcinoma | Extensive-stage Small-cell Lung Cancer | MSI-H Cancer | Cancer With A High Tumor Mutational Burden

United States, Canada
University of Arizona
National Cancer Institute (NCI)

Completed

Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma

Head and Neck Cancer | Recurrent Head and Neck Squamous Cell Carcinoma | Oropharyngeal Cancer | HNSCC | Recurrent Oropharyngeal Squamous Cell Carcinoma | Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma | Stage IVA Nasal Cavity and... and other conditions

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer

Unrectable or Locally Recurrent Hepatocellular Carcinoma

United States
AstraZeneca
Parexel

Approved for marketing

Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Ovarian Cancer

United States
Graceway Pharmaceuticals, LLC

Completed

A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence

Basal Cell Carcinoma

United States

Clinical Trials on Recurrent Platinum-Resistant Ovarian Carcinoma in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations